43 results about "Heparan sulfate" patented technology

Disclosed is a method of treating liver ischemia reperfusion (I / R) injury in a subject. In some aspects, the method comprises providing a subject suffering from liver I / R injury or at risk of suffering liver I / R injury; and administering to the subject one or more heparan sulfate (HS) compounds. In some aspects, the one or more HS compounds comprises about 5 to about 18 saccharide units, optionally about 12 to about 18 saccharide units. In some aspects, the one or more HS compounds comprises about 12 saccharide units.

The invention discloses a nanofiber membrane for inflammatory factor adsorption and a preparation method thereof, and belongs to the technical field of biomedical materials, the nanofiber membrane structurally comprises a positively charged nanofiber membrane and a negatively charged nanofiber membrane which are arranged in sequence; the positively charged nanofiber membrane is obtained by blending and electrospinning a main polymer, a positively charged ligand and a cross-linking agent which are used as raw materials and then performing in-situ cross-linking; the positively charged ligand is at least one of polylysine, polyethyleneimine, polyarginine or protamine; the electronegative charge nanofiber membrane is obtained by in-situ cross-linking after blending and electrospinning of a main polymer, an electronegative charge ligand and a cross-linking agent which are used as raw materials; the negatively charged ligand is at least one of heparin, chondroitin sulfate or heparan sulfate. The nanofiber membrane is simple in preparation process, the surface of the membrane has abundant charge binding sites, the charge density is large, the mechanical strength is high, and the adsorption effect on inflammatory factors is good.

The invention provides an application of OPO and a composition thereof in promoting intestinal development. The 1, 3-dioleoyl-2-palmitin disclosed by the invention can be used for up-regulating the transcriptional level of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

The invention relates to the technical field of artificial design of enzymes, in particular to an artificial intelligence design and expression system construction method and system for lysosomal membrane protein type N-acetyltransferase with 11 transmembrane regions, and the method comprises the following steps: collecting reaction rate information of an enzyme and a substrate, associating a structure model with rate parameters, and comparing three-dimensional difference of residues, according to the method, by collecting the reaction rate correlation structure conformation, dynamic recognition of the key conformation state is achieved, the accuracy of three-dimensional space difference analysis is improved, host expression optimization factors are fused in the construction process, and the construction efficiency is improved. According to the method, the expression efficiency is improved, conformation function screening and structural stability parallel evaluation are carried out, the screening accuracy of efficient catalysis and stable expression is enhanced, three links of recognition, screening and construction are broken through, the target enzyme obtaining efficiency and expression quality are improved, and enzyme engineering is promoted to be developed towards high-throughput systematization.

This invention discloses a recombinant 2-O-sulfonyltransferase mutant and its preparation method, belonging to the field of biotechnology. The recombinant enzyme sequence is formed by fusing a truncated (E28~N356) mutant of hamster-derived 2-O-sulfonyltransferase (L119V-R188E-A240I) with an N-terminal maltose-binding protein (MBP) tag. The recombinant 2-O-sulfonyltransferase mutant exhibits higher activity, 1.9 times that of the recombinant wild type, and greater stability, retaining 86.6% of its activity after 5 days at room temperature. Furthermore, the soluble expression level of this recombinant mutant 2-O-sulfonyltransferase is increased by 5 times. This mutant, as a novel biocatalyst with high efficiency, stability, and controllable production costs, has significant application value and broad industrialization prospects in the industrial enzymatic synthesis of glycosaminoglycans such as heparin and heparan sulfate.

A major obstacle in the field of biotherapeutics is the need for platform technologies that enable high bioavailability and long-term therapeutic exposure of biotherapies in localized disease. Traditional approaches result in problematic trade-offs, such as toxicity and off-target side effects. The present disclosure provides compounds comprising follistatin domain 1 (FSD1) of follistatin (FST), which can bind to biological structures, such as the extracellular matrix, via heparan sulfate without the undesired neutralizing effects on the activity of activin A, myostatin, and GDF11, as full-length follistatin does. The present invention relates to fusion or conjugated proteins, compositions thereof, constructs or vectors encoding them, their medical uses, and methods for biotherapeutics.

The invention provides a preparation method and application of a dairy product for promoting development of an intestinal tract glycocalyx layer. Comprising a specific dose of casein phosphopeptides, and can up-regulate the transcriptional levels of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2. Therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

The present invention relates to a pharmaceutical composition for preventing or treating Sanfilippo syndrome type A (MPS IIIA) comprising heparan N-sulfatase (HNS), and more particularly, to an optimal dose and period of administration of heparan N-sulfatase, which can effectively reduce the accumulation of heparan sulfate (HS) while improving the cognition of patients. According to the present invention, it can be used as enzyme replacement therapy (ERT) for treating Sanfilippo syndrome type A.

The present invention provides a mediated CA16 inactivated vaccine, comprising an immunizing amount of CoxA16 virus inactivated purified antigen, and also comprising glycerol, sucrose, squalene, Tween-20 and heparan sulfate. The present invention provides a mediated CA16 inactivated vaccine that can be used to prepare immunization through a specific immune mode. After the vaccine product enters the respiratory mucosal cells through cell internalization, it can stimulate the natural immune system in the epithelial cells, promote the recognition of viral antigens by the DC system and T / B cells, and the activation and differentiation of the specific immune system.

The invention discloses preparation and application of toad skin heparinoid sulfate capable of inhibiting activity of new spike protein. The preparation method comprises the following steps: crushing dried toad skin, heating in a water bath to swell, carrying out enzymolysis by using alkaline protease, and carrying out alcohol precipitation, anion exchange column purification, dialysis and freeze drying to obtain a toad skin glycosaminoglycan crude extract; crude toad skin glycosaminoglycan extracts are subjected to enzymolysis through chondroitin sulfate ABC enzyme, and the toad skin heparinoid sulfate is obtained through gel chromatographic column purification, desalination and freeze drying. The average molecular weight of the toad skin heparinoid sulfate is 11Kda, the toad skin heparinoid sulfate is composed of disaccharide units formed by connecting hexuronic acid and glucosamine through 1-4 glucosidic bonds, and the total sulfation degree of the C-2-oxygen site of hexuronic acid and the total sulfation degree of the C-6-oxygen site and the total sulfation degree of the N-site of glucosamine are 11.45%, 33.68% and 46.46% respectively. The toad skin heparinoid sulfate has competitive activity of inhibiting binding of new crown spike protein and heparin, and can prevent initial infection of new crown virus. The invention lays an important foundation for the development of new clinical application of the toad skin.

The present relates to a pharmaceutical composition for use in the treatment of ischemic stroke. The present invention has an application in particular in the therapeutic and pharmaceutical fields.

The invention relates to the field of filter materials, in particular to a melt-blown PBT non-woven fabric composite filter material and a preparation method and application thereof. The melt-blown PBT non-woven fabric composite filter material comprises a protecting net layer, a filter paper layer and a bottom layer PBT melt-blown fabric, and is characterized in that the bottom layer PBT melt-blown fabric is prepared from heparinized TPU and PBT according to the weight ratio of 1: (3-5), and a preparation method of the heparinized TPU comprises the steps that 1, TPU is dissolved to obtain a TPU solution, and the temperature is reduced to 38-42 DEG C; 2) dissolving heparan sulfate to obtain a heparan sulfate solution; the filtering material has the advantages that the heparinized TPU is obtained by compounding the TPU modified by heparan sulfate and PBT (polybutylene terephthalate), the thrombus risk in the blood filtering process is obviously reduced, and the platelet decline rate in the blood filtering process is as low as 25.4-14.9%.

Enhanced recombinant adeno-associated viruses (rAAVs) (e.g., rAAV2, rAAVrh8R, etc.) are provided herein for improved gene therapy of eye or central nervous system (CNS) disorders, wherein the rAAV comprises one or more amino acid substitutions that interact with the heparan sulfate proteoglycan. The invention provides methods for enhancing retinal cell transduction and methods for treating eye diseases with enhanced compositions of rAAV particles. Furthermore, enhanced recombinant adeno-associated viruses (rAAVs) (e.g., rAAV2, rAAVrh8R, etc.) are provided herein for improved gene therapy of CNS disorders. The invention provides methods for delivering the rAAV to the CNS, methods for treating CNS disorders with enhanced compositions of rAAV particles, and kits for delivering the rAAV to the CNS and / or treating a CNS disorder.

To obtain a heparin-like substance with high biological activity (anticoagulation activity) as heparin. A method for producing a heparin-like substance is provided, which comprises the step of culturing an animal cell to which the followings are introduced to obtain a culture supernatant containing a heparin-like substance: a polynucleotide encoding glucosaminyl N-deacetylase / N-sulfotransferase (NDST2); a polynucleotide encoding heparan sulfate 3-O-sulfotransferase 1 (Hs3st1); a polynucleotide encoding the extracellular domain of syndecan (SDC); and a polynucleotide encoding 6-O-sulfotransferase.

The invention provides application of cheese protein zymolyte in promoting intestinal development. The casein zymolyte provided by the invention can up-regulate the transcriptional levels of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

The present disclosure relates to heparan sulfate transgenic models and methods of use thereof.

The invention provides application of casein phosphopeptides in promoting development of intestinal glycocalyx layers and preparing related products. The casein phosphopeptide provided by the invention can up-regulate the transcriptional level of a coding gene gpc1 of phospholipid globulin glycan, the transcriptional level of a coding gene has1 of hyaluronic acid synthetase 1, the transcriptional level of a coding gene has2 of hyaluronic acid synthetase 2, the transcriptional level of a coding gene has3 of hyaluronic acid synthetase 3, the transcriptional level of a coding gene ext1 of exosome glycosyltransferase 1 and the transcriptional level of a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

According to the invention there is provided methods for making heparan sulfate with increased anticoagulant activity wherein the resulting product has a lower heterogeneity and presents an improved safety profile compared to conventional animal-sourced heparin.

The invention belongs to the technical field of biology, and relates to nano antibody mutation design and virus infection blocking, in particular to a mutant nano antibody Mut-Nbs1 for resisting PCV2 cell surface molecule heparan sulfate (HS) and application of the mutant nano antibody Mut-Nbs1. On the basis of a nano antibody crystal structure (PDB ID:: 7TJC), the mutant nano antibody Mut-Nbs1 is obtained through molecular docking, alanine scanning and virtual saturation mutation technologies. The mutant nano antibody Mut-Nbs1 specifically bound with HS is obtained, and the mutation site of the mutant nano antibody Mut-Nbs1 is PHE47gt; aRG, ASP < 99gt >; tYR, TYR 108gt, TYR 108gt; a PRO; eLISA results show that Mut-Nbs1 can be combined with HS in a high affinity manner, has no cross reaction with small molecules of other HS structural analogues, has good affinity and specificity, has the characteristics of high efficiency, rapidness and low cost, and has a wide application prospect.

The invention provides formula milk powder as well as a preparation method and application thereof in promoting intestinal protection or repair. The formula milk powder disclosed by the invention comprises cheese protein zymolyte, and transcriptional levels of an encoding gene gpc1 capable of up-regulating phospholipid globulin glycan, an encoding gene has1 of hyaluronic acid synthetase 1, an encoding gene has2 of hyaluronic acid synthetase 2, an encoding gene has3 of hyaluronic acid synthetase 3, an encoding gene ext1 of exosome glycosyltransferase 1 and an encoding gene ext2 of exosome glycosyltransferase 2, therefore, the formation of a protein skeleton of a glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the formation of the glycocalyx layer is further promoted, and the effects of perfecting an intestinal barrier, regulating intestinal flora, improving intestinal health and promoting intestinal protection or repair are achieved.

The present invention relates to a lyophilized preparation containing, as an active ingredient, a fusion protein of an antibody and heparan N-sulfatase (SGSH), the lyophilized preparation further comprising an isotonic agent, a nonionic surfactant, and a buffering agent, wherein the nonionic surfactant contains polysorbate and poloxamer, and the buffering agent contains histidine.

The invention relates to the technical field of aquaculture, in particular to application of heparan sulfate in prevention and treatment of grass carp reovirus. The heparan sulfate is competitively combined with the grass carp reovirus, so that the virus adsorption and infection process can be effectively inhibited. In drugs, fish feed and additives, when the concentration of heparan sulfate exceeds 0.1 mu g / mL or 10mg / kg, the effect of resisting grass carp reovirus is obviously shown. Cell experiments and artificial infection challenge experiments prove that the virus infection rate can be reduced, the survival rate can be increased, and tissue damage can be reduced. As an antiviral feed additive, the heparan sulfate provided by the invention has the advantages of low cost, small dosage, high safety and the like, provides a new strategy for preventing and treating viral diseases in the aquaculture industry, and has a wide application prospect.

Provided herein include sulfated glycosaminoglycans including sulfated disaccharides, tetrasaccharides, and oligosaccharides and methods of synthesizing heparan sulfate disaccharide, tetrasaccharide, oligosaccharide library in solution-phase. Provided herein also includes a method of treating neurological diseases or disorders with sulfated glycosaminoglycans such as 4-O-sulfated chondroitin sulfate polysaccharides.

The invention concerns an immunomodulatory fusion protein comprising a Fc fragment of immunoglobulin which binds Fc receptor expressed on the surface of APC, NK or NKT cells, and a Tat polypeptide which is a polypeptide of SEQ ID NO: 1 or a variant which binds heparan sulfate, providing that the fusion protein does not comprise the peptide Tat 49-57, and its use in immunotherapy of cancer, infectious, immunoinflammatory or autoimmune diseases.

To provide methods for generation of cytocapsulae and cytocapsular tubes.SOLUTION: A method of generating cytocapsulae and cytocapsular tubes includes implanting cells in the top of a 3D matrix, and incubating the cell implanted 3D matrix under conditions where the cells engender the cytocapsulae and cytocapsular tubes. In one aspect, the 3D matrix comprises elastin, laminin, collagen, proteoglycans, or non-proteoglycan polysaccharide, and the proteoglycans include heparan sulfate, chondroitin sulfate, and keratin sulfate.SELECTED DRAWING: None

The invention discloses heparan sulfate N-deacetylation / N-sulfotransferase with improved enzyme activity and a production method of heparan sulfate N-deacetylation / N-sulfotransferase, and belongs to the technical field of biology. The human heparan sulfate N-deacetylation / N-sulfotransferase is subjected to truncation mutation, connecting peptide optimization, site-specific mutagenesis and superposition mutation, the specific enzyme activity of the obtained mutant reaches 6.7 * 10 < 3 > U / mg and is improved by 118% compared with that of an original strain, the sulfonation modification level of 1g / L of N-sulfonated heparin precursor can be improved to 80% or above, and the specific enzyme activity of the obtained mutant is greatly improved. The sulfated modification level of the intracellular synthesized N-sulfated heparin precursor can reach 90% or above, the requirement for highly sulfated modification of heparin is met, and a solid foundation is laid for large-scale production of biosynthesized heparin.

The invention provides application of lactoferrin and a composition thereof in promoting intestinal development. The lactoferrin provided by the invention can up-regulate the transcriptional level of a coding gene gpc1 of phospholipid globulin glycan, the transcriptional level of a coding gene has1 of hyaluronic acid synthetase 1, the transcriptional level of a coding gene has2 of hyaluronic acid synthetase 2, the transcriptional level of a coding gene has3 of hyaluronic acid synthetase 3, the transcriptional level of a coding gene ext1 of exosome glycosyltransferase 1 and the transcriptional level of a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

The present invention provides a composition for improving the epidermal junction layer and its application. It was found that the combination of a symbiotic fermentation product of Thermus thermophilus and Bacillus sp. and grape seed extract synergistically improves the expression of proteins associated with the epidermal junction layer, increasing the expression of occludin by 316%, heparan sulfate proteoglycan (HSPG) by 64%, and hyaluronic acid receptor protein (CD44) by 69%. Compared with single ingredients, this composition is more effective in improving the health of the epidermal junction layer. It can be used to prepare cosmetics to meet the urgent need for anti-aging, has good application prospects, and also provides a new approach to the development of traditional anti-aging skin care products.

Methods and compositions for diagnosing, preventing or treating a viral infection in a subject comprising administering to a subject in need thereof an effective amount of a glycosidase or a sulfatase to degrade a glycan, such as heparan sulfate, to inhibit viral infection, such as COVID-19. Methods for identifying a glycosidase, a sulfatase, or a microbe associated with increased susceptibility to viral infection in a subject.

Disclosed are assays for screening active compounds interfering with interaction between chitinase-like protein YKL-40 and chitin oligomers, as well as interfering with interaction between chitinase-like protein YKL-40 and heparan sulfate. Moreover, disclosed are active compounds identified by these assays as inhibitors of chitinase-like protein YKL-40, their therapeutic applications, and their use in biosensors measuring the level of chitinase-like protein YKL-40 in biological samples.